Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach - PubMed (original) (raw)
Review
. 2018 Apr;70(2):348-383.
doi: 10.1124/pr.117.014753.
Gina Manda 2, Ahmed Hassan 2, María José Alcaraz 2, Coral Barbas 2, Andreas Daiber 2, Pietro Ghezzi 2, Rafael León 2, Manuela G López 2, Baldo Oliva 2, Marta Pajares 2, Ana I Rojo 2, Natalia Robledinos-Antón 2, Angela M Valverde 2, Emre Guney 1, Harald H H W Schmidt 2
Affiliations
- PMID: 29507103
- DOI: 10.1124/pr.117.014753
Free article
Review
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Antonio Cuadrado et al. Pharmacol Rev. 2018 Apr.
Free article
Abstract
Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This network joins apparently heterogeneous phenotypes such as autoimmune, respiratory, digestive, cardiovascular, metabolic, and neurodegenerative diseases, along with cancer. Importantly, this approach matches and confirms in silico several applications for NRF2-modulating drugs validated in vivo at different phases of clinical development. Pharmacologically, their profile is as diverse as electrophilic dimethyl fumarate, synthetic triterpenoids like bardoxolone methyl and sulforaphane, protein-protein or DNA-protein interaction inhibitors, and even registered drugs such as metformin and statins, which activate NRF2 and may be repurposed for indications within the NRF2 cluster of disease phenotypes. Thus, NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked. The resulting NRF2 drugome may therefore rapidly advance several surprising clinical options for this subset of chronic diseases.
Copyright © 2018 by The Author(s).
Similar articles
- Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood.
Bourdakou MM, Fernández-Ginés R, Cuadrado A, Spyrou GM. Bourdakou MM, et al. Redox Biol. 2023 Nov;67:102881. doi: 10.1016/j.redox.2023.102881. Epub 2023 Sep 7. Redox Biol. 2023. PMID: 37696195 Free PMC article. - Nrf2, the Master Regulator of Anti-Oxidative Responses.
Vomund S, Schäfer A, Parnham MJ, Brüne B, von Knethen A. Vomund S, et al. Int J Mol Sci. 2017 Dec 20;18(12):2772. doi: 10.3390/ijms18122772. Int J Mol Sci. 2017. PMID: 29261130 Free PMC article. Review. - Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS, Huang Q, Ho CT, Wang YJ, Pan MH. Chiou YS, et al. Free Radic Biol Med. 2016 May;94:1-16. doi: 10.1016/j.freeradbiomed.2016.02.010. Epub 2016 Feb 12. Free Radic Biol Med. 2016. PMID: 26878775 - Nrf2 in health and disease: current and future clinical implications.
Al-Sawaf O, Clarner T, Fragoulis A, Kan YW, Pufe T, Streetz K, Wruck CJ. Al-Sawaf O, et al. Clin Sci (Lond). 2015 Dec;129(12):989-99. doi: 10.1042/CS20150436. Clin Sci (Lond). 2015. PMID: 26386022 Review. - NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases.
Cores Á, Piquero M, Villacampa M, León R, Menéndez JC. Cores Á, et al. Biomolecules. 2020 Jun 14;10(6):904. doi: 10.3390/biom10060904. Biomolecules. 2020. PMID: 32545924 Free PMC article. Review.
Cited by
- Noise-Induced Vascular Dysfunction, Oxidative Stress, and Inflammation Are Improved by Pharmacological Modulation of the NRF2/HO-1 Axis.
Bayo Jimenez MT, Frenis K, Kröller-Schön S, Kuntic M, Stamm P, Kvandová M, Oelze M, Li H, Steven S, Münzel T, Daiber A. Bayo Jimenez MT, et al. Antioxidants (Basel). 2021 Apr 19;10(4):625. doi: 10.3390/antiox10040625. Antioxidants (Basel). 2021. PMID: 33921821 Free PMC article. - NRF2 Is an Upstream Regulator of MYC-Mediated Osteoclastogenesis and Pathological Bone Erosion.
Park PSU, Mun SH, Zeng SL, Kim H, Bae S, Park-Min KH. Park PSU, et al. Cells. 2020 Sep 21;9(9):2133. doi: 10.3390/cells9092133. Cells. 2020. PMID: 32967239 Free PMC article. - Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease.
Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT, Vujacic-Mirski K, Helmstädter J, Kröller-Schön S, Münzel T, Daiber A. Steven S, et al. Oxid Med Cell Longev. 2019 Jun 23;2019:7092151. doi: 10.1155/2019/7092151. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31341533 Free PMC article. Review. - Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity.
Gao W, Guo L, Yang Y, Wang Y, Xia S, Gong H, Zhang BK, Yan M. Gao W, et al. Front Cell Dev Biol. 2022 Feb 2;9:809952. doi: 10.3389/fcell.2021.809952. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35186957 Free PMC article. Review. - NRF2 Protects against Altered Pulmonary T Cell Differentiation in Neonates Following In Utero Ultrafine Particulate Matter Exposure.
Lau CH, Pendleton D, Drury NL, Zhao J, Li Y, Zhang R, Wright GA, Hoffmann AR, Johnson NM. Lau CH, et al. Antioxidants (Basel). 2022 Jan 21;11(2):202. doi: 10.3390/antiox11020202. Antioxidants (Basel). 2022. PMID: 35204086 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical